InflaRx to Showcase Izicopan Pre-Clinical Data at Kidney Week 2026
Event summary
- InflaRx selected for late-breaking poster session at Kidney Week 2026, October 22.
- Izicopan, an oral C5aR1 antagonist, shows promising pre-clinical results in kidney disease models.
- Compound demonstrates favorable pharmacokinetic/pharmacodynamic profile and safety in Phase 2a studies.
- Izicopan targets ANCA-associated vasculitis and other renal indications.
The big picture
InflaRx's presentation at Kidney Week 2026 highlights the growing interest in complement system inhibition for renal diseases. The company's focus on oral administration and favorable drug interaction profile positions it competitively in a space dominated by injectable therapies. Success in this area could expand InflaRx's market reach beyond its current lead program, vilobelimab, into a broader range of inflammatory conditions.
What we're watching
- Clinical Progression
- Whether Izicopan's promising pre-clinical data translates into successful Phase 3 trials for renal indications.
- Competitive Positioning
- How InflaRx differentiates Izicopan from existing C5aR inhibitors, particularly in avoiding CYP3A4 inhibition.
- Market Opportunity
- The pace at which InflaRx can expand Izicopan's indications beyond AAV into other renal diseases.